Autism Diagnostic Observation Schedule

AUTISM THERAPY PROVIDER TO EXPAND SERVICES TO ILLINOIS

Retrieved on: 
Monday, January 10, 2022
ABC, Autism, National Parkway, Suite, Autism Diagnostic Observation Schedule, CEO, GLOBE, Burr Ridge, Illinois, Applied behavior analysis, Industry, Education, Diagnosis, Neurology, ABA, Pediatrics, Residential care, Medicine, Television

Austin, Texas, Jan. 10, 2022 (GLOBE NEWSWIRE) -- To help meet the growing need for therapy services for children with autism in Illinois, Action Behavior Centers (ABC), one of the countrys largest autism services providers announced it will expand its footprint by opening 10 new Applied Behavior Analysis (ABA) therapy centers in the state, beginning this month with centers opening in Naperville and Schaumburg.

Key Points: 
  • Austin, Texas, Jan. 10, 2022 (GLOBE NEWSWIRE) -- To help meet the growing need for therapy services for children with autism in Illinois, Action Behavior Centers (ABC), one of the countrys largest autism services providers announced it will expand its footprint by opening 10 new Applied Behavior Analysis (ABA) therapy centers in the state, beginning this month with centers opening in Naperville and Schaumburg.
  • As a former Chicagoan myself, Im beyond excited to offer life-altering services to children with autism.
  • With more than 70 ABA therapy centers established throughout Texas, Arizona, and Colorado, ABC currently provides autism therapy services to thousands of children with autism and their families.
  • Founded in 2017, Action Behavior Centers (ABC) is a leading applied behavior therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum.

PaxMedica Presents Clinical Data and New Analyses from a Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) at the 2021 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting

Retrieved on: 
Thursday, October 28, 2021
Safety, Lists of diseases, Autism, MD, Research, Securities Act of 1933, Industry, AACAP, Status epilepticus, Ageing, Myalgia, Private Securities Litigation Reform Act, ABC, FDA, Suramin, Neuroinflammation, Cerebral palsy, Hydrocephalus, Autism Diagnostic Observation Schedule, SAE, ASD, VP, Medicine, Nature, Arm, Adolescence, Company, The Company, Seizure, COVID-19, Work, Psychiatry, Fragile X-associated tremor/ataxia syndrome, Drug Quality and Security Act, Degenerative disease, Population, Neurodevelopmental disorder, Autism spectrum, Securities Exchange Act of 1934, Pharmaceutical industry

The study was conducted at 6 sites in South Africa where suramin is an approved medicine.

Key Points: 
  • The study was conducted at 6 sites in South Africa where suramin is an approved medicine.
  • The protocol was approved by the South Africa Health Products Regulatory Authority and each site's Institutional Review Board or Ethics Committee.
  • Subjects were diagnosed with ASD by DSM-5 criteria and severity was measured by the Autism Diagnostic Observation Schedule.
  • Forty-four subjects completed the study with 8 early withdrawals [COVID-19: 5, serious adverse event (SAE): 1, other reasons: 2].

Results from Axial Therapeutics Phase 1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms

Retrieved on: 
Thursday, December 3, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Mental health, Clinical trials, Other Health, Abnormal psychology, Autism, Branches of biology, Pervasive developmental disorders, Psychiatry, Communication disorders, Psychiatric diagnosis, Childhood psychiatric disorders, Autism Diagnostic Observation Schedule, Tolerability, ASD, the Presentation at Synchrony Symposium, Axial Therapeutics

The findings from the open-label clinical study demonstrated that AB-2004, Axials first-in-class, orally administered therapeutic, met the primary endpoint demonstrating safety, tolerability and adherence with no drug-related adverse events.

Key Points: 
  • The findings from the open-label clinical study demonstrated that AB-2004, Axials first-in-class, orally administered therapeutic, met the primary endpoint demonstrating safety, tolerability and adherence with no drug-related adverse events.
  • Specifically, the data showed that AB-2004 reduced several key GI neuroactive microbial metabolites (NMMs) measured in plasma and urine.
  • The Phase 1b/2a study evaluated the safety and tolerability of AB-2004 in males aged 12 to 17 with autism spectrum disorder (ASD) across three sites in Australia and New Zealand.
  • Each subject had a confirmed diagnosis of autism via the Autism Diagnostic Observation Schedule (ADOS) and suffered from GI symptoms.

Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

Retrieved on: 
Tuesday, March 3, 2020
Psychiatry, Abnormal psychology, Autism, Psychiatric diagnosis, Pervasive developmental disorders, Health, Communication disorders, Developmental neuroscience, Autism spectrum, Autism Diagnostic Observation Schedule, Developmental disorder, Spectrum disorder

These data will also be presented during the ASENT Pipeline Data Blitz session on Wednesday March 4, 2020 from 1:00 to 3:00PM EST.

Key Points: 
  • These data will also be presented during the ASENT Pipeline Data Blitz session on Wednesday March 4, 2020 from 1:00 to 3:00PM EST.
  • The meeting is being held in Bethesda, MD on March 2nd through March 5th, 2020.
  • These include the Aberrant Behavior Checklist Community (ABC-C); the Autism Diagnostic Observation Schedule (ADOS-2); and the Parent Rated Anxiety ScaleAutism Spectrum Disorder (PRAS-ASD).
  • ASD is a complex neurodevelopmental disorder characterized by difficulties with behaviors, communication, and social interaction,said Dr. Palumbo.